Abstract:ID 98732 Poster Board 486 Addiction to tobacco and nicotine products remains a leading cause of disease and death worldwide, and an increasing number of never-smokers are being exposed to nicotine via e-cigarettes. With only a few moderately efficacious smoking-cessation therapeutics available, achieving long-term abstinence from nicotine addiction is an unattainable goal for millions. The role of brain nicotinic acetylcholine receptors (nAChRs) in nicotine's behavioral effects leading to tobacco addiction is well recognized. However, the neurobiological basis underlying the role of specific nAChRs in nicotine's behavioral effects remains poorly understood. Our recently published findings have emphasized the role of the high-sensitivity isoform of the α4β2 nAChRs (the HS (α4)2(β2)3 nAChR) in nicotine-associated behavior. Therefore, our current efforts are focused on the development of novel positive allosteric modulators (PAMs) that selectively target the HS (α4)2(β2)3 nAChR for in vivo applications to probe the function of this major nAChR subtype as well as for potential therapeutic applications as smoke-cessation aid. Unlike classical nAChR agonists, which bind at the evolutionary conserved ACh binding site, PAMs bind to sites that are less conserved and potentially unique to the HS (α4)2(β2)3 nAChR making the subtype selectively more attenable. In addition, PAMs act only in the presence of the endogenous neurotransmitter, minimizing tonic activation, desensitization, receptor upregulation, and alteration in the pattern of cholinergic synaptic transmission seen with nAChR agonists. Using three nAChR PAM pharmacophores and computational ligand docking predictions, we synthesized a series of derivatives and examined their nAChR PAM activities (ability to enhance ACh-induced current responses) in vitro . Candidates with potent and efficacious in vitro HS (α4)2(β2)3 nAChR PAM activities are currently being evaluated for their ability to reduce nicotine self-intake and withdrawal symptoms in mice.

Synthesis and Biological Evaluation of Novel Hybrids of Highly Potent and Selective Α4β2-Nicotinic Acetylcholine Receptor (nachr) Partial Agonists.

Discovery of Highly Potent and Selective Α4β2-Nicotinic Acetylcholine Receptor (nachr) Partial Agonists Containing an Isoxazolylpyridine Ether Scaffold That Demonstrate Antidepressant-like Activity. Part II

Chemistry And Pharmacological Characterization Of Novel Nitrogen Analogues Of Amop-H-Oh (Sazetidine-A, 6[5-(Azetidin-2-Ylmethoxy)Pyridin-3-Yl]Hex-5-Yn-L-Ol) As Alpha 4 Beta 2-Nicotinic Acetylcholine Receptor-Selective Partial Agonists

Identification Of Novel Alpha 4 Beta 2-Nicotinic Acetylcholine Receptor (Nachr) Agonists Based On An Isoxazole Ether Scaffold That Demonstrate Antidepressant-Like Activity

Chemistry and Behavioral Studies Identify Chiral Cyclopropanes As Selective Α4β2-Nicotinic Acetylcholine Receptor Partial Agonists Exhibiting an Antidepressant Profile.

Chemistry, Pharmacology, and Behavioral Studies Identify Chiral Cyclopropanes As Selective Α4β2-Nicotinic Acetylcholine Receptor Partial Agonists Exhibiting an Antidepressant Profile. Part II.

Structure–Activity Studies of Diazabicyclo[3.3.0]octane-Substituted Pyrazines and Pyridines As Potent Α4β2 Nicotinic Acetylcholine Receptor Ligands

Insights into the Structural Determinants Required for High-Affinity Binding of Chiral Cyclopropane-Containing Ligands to Α4β2-Nicotinic Acetylcholine Receptors: an Integrated Approach to Behaviorally Active Nicotinic Ligands

Synthesis And Structure-Activity Relationships Of Pyridine-Modified Analogs Of 3-[2-((S)-Pyrrolidinyl)Methoxy]Pyridine, A-84543, A Potent Nicotinic Acetylcholine Receptor Agonist

The Potent and Selective Α4β2/α6-Nicotinic Acetylcholine Receptor Partial Agonist 2-[5-[5-((s)azetidin-2-ylmethoxy)-3-pyridinyl]-3-isoxazolyl]ethanol Demonstrates Antidepressive-Like Behavior in Animal Models and a Favorable ADME-tox Profile.

Design of novel 3,6-diazabicyclo[3.1.1]heptane derivatives with potent and selective affinities for α4β2 neuronal nicotinic acetylcholine receptors

Design and Synthesis of New Agents for Neuronal Nicotinic Acetylcholine Receptor (nachrs) Imaging.

Novel Positive Allosteric Modulators of the Human Α7 Nicotinic Acetylcholine Receptor

Development of Antidepressant Drugs Through Targeting Α4β2-Nicotinic Acetylcholine Receptors

Recent Developments in Novel Antidepressants Targeting Α4β2-Nicotinic Acetylcholine Receptors.

Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.

Discovery of Fused Heterocyclic Carboxamide Derivatives As Novel Α7-Nachr Agonists: Synthesis, Preliminary SAR and Biological Evaluation.

Synthesis and Biological Evaluation of Novel Triazine Derivatives as Positive Allosteric Modulators of α7 Nicotinic Acetylcholine Receptors

Novel Pyridyl Ring C5 Substituted Analogues Of 3-(1-Methyl-2(S)- Pyrrolidinylmethoxy)Pyridine (A-84543) As Highly Selective Agents For Neuronal Nicotinic Acetylcholine Receptor(Nachr)

Optimizing positive allosteric modulators to selectively target the high sensitivity 23 nicotinic acetylcholine receptor

The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: carboxamide derivatives with different spacer motifs